Amy Chesire (University of Rochester) and Greg Suter (Hereditary Neurological Disease Centre) are long-time site coordinators for clinical trials in Huntington's disease. On this episode of the HD Insights Podcast, we spoke with both about their history of working with clinical study participants and their current experience with participants on the KINECT-HD study. KINECT-HD is a Phase 3, randomized, double-blind, placebo-controlled study investigating valbenazine for treatment of chorea in Huntington disease. The study is being conducted at sites across the U.S. and Canada. Additional information about the study can be found at www.KINECT-HD.org.